Our data-driven, science-first drug development mindset inspires us to pursue meaningful treatments to help cancer patients recover stronger and live longer.

Striving to give hope to patients living with cancer

Our success in advancing clinical programs and establishing a commercial product franchise has been fueled by our team’s fervent belief in the science behind our molecules. 

Exelixis programs

Partnered programs

Partnered programs

COTELLIC® (cobimetinib) tablets
MINNEBRO® (esaxerenone)
Marketed by Daiichi Sankyo and available in Japan, only

U.S. Medical Support

Adverse Event Reporting
If you want to report an adverse event related to use of CABOMETYX® (cabozantinib) or COMETRIQ® (cabozantinib), please email or call 1-855-500-3935 (EXEL).

Product Quality Complaints
If you want to report a product quality complaint related to use of CABOMETYX or COMETRIQ, please call 1-855-500-3935 (EXEL).

Medical Information Questions
If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at or call 855-292-3935 (EXEL).

You are now leaving the website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.